Lv4
440 积分 2021-03-02 加入
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy
6小时前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
1个月前
已完结
Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus
2个月前
已完结
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
4个月前
已完结
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
4个月前
已完结
Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies
4个月前
已关闭
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
5个月前
已完结
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors
5个月前
已完结
Phase I Study of Allogeneic Anti-CD19 CAR-T Therapy for Patients with CD19+ Relapsed/Refractory Acute B-Lymphoblastic Leukemia
5个月前
已关闭
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
6个月前
已完结
皖公网安备34019202002308
